Contraindications: - Personal or family history of medullary thyroid carcinoma (MTC) - Multiple Endocrine Neoplasia syndrome type 2 (MEN2) - Serious hypersensitivity to orforglipron Safety profile: Common adverse effects include nausea, diarrhea, constipation, vomiting, abdominal pain, and fatigue
Despite the common use of pharmacotherapy in obesity management, sarcopenia and SO remain significant concerns [12]
In normal circumstances, mast cells release various compounds called mediators in response to foreign substances to keep us safe
We closely monitor your safety and comfort throughout your treatment
Originally approved for type 2 diabetes, GLP-1 medications surged in popularity for another reason: weight loss
In cells incubated with [ 13 C 5 ]KIV, we observed increases in the concentrations of M4 isobutyrylcarnitine and M4 3HIB as the dose of BCATi increased, consistent with a shift toward higher use of the labeled substrate due to inhibition of reverse transamination (Supplemental Figure 2, B and C)
